secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001628280-23-037816
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex reports Q3 2023 net sales $19.5M (+14% YoY), positive adjusted EBITDA $0.5M
--------------------------------------------------------------------------------

- Total net sales $19.5M (+14% YoY); Tru Niagen sales $17.4M (+19% YoY).
- Gross margin 61.4% (up 160 bps); net loss $1.0M ($0.01 loss per share).
- Adjusted EBITDA positive $0.5M, a $1.7M improvement from Q3 2022.
- Cash $26.8M, no debt; positive operating cash flows for third consecutive quarter.
- Launched Tru Niagen on iHerb in Aug; launched 1,000mg dosage in Oct; Zesty Paws partnership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828023037816/0001628280-23-037816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828023037816/cdxc-20231108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-037816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer